慢性阻塞性肺病（COPD）市場:KOL的洞察

本報告提供全球慢性阻塞性肺病（COPD）市場相關調查，市場概要，以及已上市治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

治療流程

調查目的

ICS/LABA/LAMA的3劑聯合治療

• 已上市治療方法

生物學的療法

• 抗IL5開發平台治療
• 抗IL4/IL13開發平台治療
• 抗TSLP開發平台治療
• 抗IL33開發平台治療

磷酸二酯[酉每]抑制劑

• 開發平台療法

未來的治療範例

• 主要的洞察摘要

附錄

KOL快報

Explore the breakthrough potential of Dupixent for eosinophilic COPD, on the cusp of regulatory approval in the US and Europe, heralded by convincing Phase III results. Gain insights into the competitive landscape with updates on Nucala and Fasenra's clinical trials, highlighting the strategic positioning of biologics in COPD treatment. Stay informed on the latest advancements and prepare for the impact on COPD management.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (8)

ICS/LABA/LAMA triple combination therapies (10)

• Marketed therapies (10)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK), Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi), and Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate; AstraZeneca) (10)

Biological therapies (50)

• Anti-IL5 pipeline therapies (12)
  • Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (12)
• Anti-IL4/IL13 pipeline therapies (8)
  • Dupixent (dupilumab; Regeneron/Sanofi) (8)
• Anti-TSLP pipeline therapies (7)
  • Tezspire (tezepelumab; Amgen/AstraZeneca) (7)
• Anti-IL33 pipeline therapies (23)
  • Itepekimab (REGN3500/SAR440340; Regeneron/Sanofi) (9)
  • Astegolimab (RG6149; Roche) (9)
  • Tozorakimab (MEDI3506; AstraZeneca) (5)

Phosphodiesterase inhibitors (24)

• Pipeline therapies (24)
  • Ensifentrine (RPL554; Verona) (13)
  • Tanimilast (CHF 6001; Chiesi) (11)

Future treatment paradigm (11)

• Key insights summary (11)

Appendix (5)

• KOL details (5)
  • KOLs from North America (1)
  • KOLs from the EU (3)

KOL Bulletins (2)